289 related articles for article (PubMed ID: 33784797)
1. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
[TBL] [Abstract][Full Text] [Related]
2. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
3. Soyasaponin A
Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
5. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
7. Alanyl-Glutamine Protects Mice against Methionine- and Choline-Deficient-Diet-Induced Steatohepatitis and Fibrosis by Modulating Oxidative Stress and Inflammation.
Hu J; Zheng Y; Ying H; Ma H; Li L; Zhao Y
Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145172
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
[TBL] [Abstract][Full Text] [Related]
9. Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice.
Li Y; Chen H; Ke Z; Huang J; Huang L; Yang B; Fan S; Huang C
Biochem Biophys Res Commun; 2020 Jan; 521(3):639-645. PubMed ID: 31679693
[TBL] [Abstract][Full Text] [Related]
10. Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis.
Huang P; Kaluba B; Jiang XL; Chang S; Tang XF; Mao LF; Zhang ZP; Huang FZ
Biomed Res Int; 2018; 2018():8071093. PubMed ID: 29670908
[TBL] [Abstract][Full Text] [Related]
11. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
12. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
14. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction.
An P; Wei G; Huang P; Li W; Qi X; Lin Y; Vaid KA; Wang J; Zhang S; Li Y; Or YS; Jiang LJ; Popov YV
Liver Int; 2020 Jul; 40(7):1655-1669. PubMed ID: 32329946
[TBL] [Abstract][Full Text] [Related]
15. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
17. Carbon tetrachloride (CCl
Zhang G; Wang X; Chung TY; Ye W; Hodge L; Zhang L; Chng K; Xiao YF; Wang YJ
BMC Gastroenterol; 2020 Oct; 20(1):339. PubMed ID: 33059584
[TBL] [Abstract][Full Text] [Related]
18. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
Rodrigues PM; Afonso MB; Simão AL; Carvalho CC; Trindade A; Duarte A; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM; Castro RE
Cell Death Dis; 2017 Apr; 8(4):e2748. PubMed ID: 28406477
[TBL] [Abstract][Full Text] [Related]
19. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
